Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 11;50(6):559-560.
doi: 10.1159/000533736. eCollection 2023 Dec.

Challenges for Plasma-Derived Medicinal Products

Rainer Moog  1 , Teija Dehmer-Laitinen  1 , Uwe Taborski  1
Affiliations

Challenges for Plasma-Derived Medicinal Products

Rainer Moog et al. Transfus Med Hemother. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors are employees at Octapharma Plasma GmbH.

References

    1. Strengers PFW. Challenges for plasma-derived medicinal products. Transfus Med Hemother. 2023;50(2):116–22. 10.1159/000528959. - DOI - PMC - PubMed
    1. Prevot J, Jolles S. Global immunoglobulin supply: streaming towards the iceberg? Curr Opin Allergy Clin Immunol. 2020;20(6):557–64. 10.1097/ACI.0000000000000696. - DOI - PMC - PubMed
    1. Hartmann J, Ragusa MJ, Burchardt ER, Manukyan Z, Popovsky MA, Leitman SF. Personalized collection of plasma from healthy donors: a randomized controlled trial of a novel technology-enabled nomogram. Transfusion. 2021;61(6):1789–98. 10.1111/trf.16389. - DOI - PMC - PubMed
    1. Moog R, Laitinen T, Taborski U. Safety of plasmapheresis in donors with low IgG levels: results of a prospective, controlled multicentre study. Transfus Med Hemother. 2022;49(5):271–9. 10.1159/000522528. - DOI - PMC - PubMed
    1. Taborski U, Laitinen T. Donor safety in an individualized plasmapheresis program - results of an interim analysis. Transfus Apher Sci. 2022;61(5):103446. 10.1016/j.transci.2022.103446. - DOI - PubMed